T1	Participants 92 156	hormone-sensitive advanced or metastatic breast cancer patients.
T2	Participants 293 327	women with advanced breast cancer.
T3	Participants 536 620	Ninety-two patients with advanced breast cancer received arzoxifene 20 or 50 mg/day.
